<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
  <front>
    <journal-meta />
    <article-meta>
      <title-group>
        <article-title>Comparing SNOMED CT</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <string-name>Jonathan Mortensen</string-name>
          <email>Jonathan.Mortensen@case.edu</email>
          <xref ref-type="aff" rid="aff0">0</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Olivier Bodenreider</string-name>
          <email>olivier@nlm.nih.gov</email>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff0">
          <label>0</label>
          <institution>Department of Biomedical Engineering, Case Western Reserve University</institution>
          ,
          <addr-line>Cleveland, Ohio</addr-line>
          ,
          <country country="US">USA</country>
        </aff>
        <aff id="aff1">
          <label>1</label>
          <institution>National Library of Medicine</institution>
          ,
          <addr-line>Bethesda, Maryland</addr-line>
          ,
          <country country="US">USA</country>
        </aff>
      </contrib-group>
      <fpage>116</fpage>
      <lpage>121</lpage>
      <abstract>
        <p>Background: Clinical decision support systems and semantic mining require interoperable representations of pharmacologic classes across reference terminological systems. We explore two such systems: NDF-RT and SNOMED CT. Methods: We evaluate the overlap of pharmacologic classes in NDF-RT (VA Classes) and SNOMED CT. We compare classes based on the set of their members (drugs) across systems, using the Jaccard coefficient as a measure of overlap between two classes. Results: There is a limited overlap among the two systems. The average Jaccard value is 0.293. Only 11.5% of the VA classes have a Jaccard value of 0.75 or above. Conclusions: The analysis of discrepancies between pharmacologic classes across systems offers a strategy for identifying classes in need of critical review. Due to the heterogeneity of the representation of pharmacologic classes in various terminologies, we recommend that drugs, not classes, be annotated in text for semantic mining purposes.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="sec-1">
      <title>Introduction</title>
      <p>
        Pharmacologic classes are typically established in
reference to some of the properties of the active
moiety, with respect to chemistry, physiology,
metabolism and therapeutic intent [
        <xref ref-type="bibr" rid="ref1">1</xref>
        ]. For example,
the classes platelet aggregation inhibitors and
anticoagulants refer to the physiologic effect of drugs
decreasing platelet aggregation and coagulation,
respectively. In contrast, the class cardiac glycoside
refers to the chemical structure of drugs such as
digoxin, while the class antianginal refers to the
therapeutic properties of some drugs on angina
pectoris. Some classes are also defined in reference to
several properties, e.g., nitrate vasodilator, referring
to both the chemical structure of nitrates and their
relaxing action on the musculature of blood vessels
(physiologic effect). In other words, pharmacologic
classes provide an abstract representation of drug
properties, useful in the context of clinical decision
support and for the annotation of biomedical
resources, including clinical text and the biomedical
literature.
      </p>
      <p>While interoperability among terminologies is a
requirement for clinical decision support, in which
decision support rules are defined in reference to
concepts in various terminologies (e.g., concepts for
drug classes), it is also important that annotations to
biomedical entities such as drug classes be consistent
within and across datasets when such datasets are
exchanged and integrated, as these annotations form
the basis for knowledge discovery through semantic
mining.</p>
      <p>
        The National Drug File - Reference Terminology
(NDF-RT) is a drug terminology produced by
the Department of Veterans Affairs in the United
States and is recommended as the standard in
eprescribing systems [
        <xref ref-type="bibr" rid="ref2">2</xref>
        ]. Other clinical terminologies
such as SNOMED CT also include pharmacologic
information.
      </p>
      <p>The objective of this work is to evaluate the
degree to which annotations to drug classes in
various terminological systems are interoperable,
with a focus on pharmacologic classes from
NDFRT. More specifically, we evaluate the overlap of
VA classes to those in SNOMED CT. The analysis
of the classes reveals discrepancies between the two
systems and offers a strategy for identifying classes
in need of critical review.</p>
    </sec>
    <sec id="sec-2">
      <title>Background</title>
      <p>In this section, we give a brief presentation of
NDFRT and SNOMED CT and present some related
work on NDF-RT.</p>
      <p>
        The National Drug File - Reference
Terminology (NDF-RT) is based upon the National
Drug File, a listing of medications produced by
the Department of Veteran Affairs [
        <xref ref-type="bibr" rid="ref3">3</xref>
        ]. It serves
as a reference standard for a variety of medical
situations related to drugs and medications.
NDFRT is a description logic-based model available in
OWL and XML formats. It includes 9 “Kinds”
of information: Cellular or Molecular
Interactions, Clinical Kinetics, Diseases Manifestations or
Physiologic States, Pharmaceutical Preparations,
Physiological Effects, RxNorm Dose Forms,
Therapeutic Categories, and VA Drug Interactions. The
Pharmaceutical Preparations hierarchy organizes
drugs into three categories: Products by Generic
Ingredient Combination, Products by VA Class and
External Pharmacologic Classes (EPC).
      </p>
      <p>There are 485 VA Drug Classes organized into
a basic hierarchy. A drug generally belongs to
only one class. Examples of VA classes include
ANTIMALARIALS, of which the clinical drug
QUININE SO4 162.5MG TAB is a member. Its
parent class is ANTIPROTOZOALS. In addition,
there are 425 EPCs (not used in this work). Differing
from the VA Classes, the EPCs have a nearly flat
hierarchy and are defined in reference to various
properties, such as physiologic effect, therapeutic
intent, ingredient and mechanism of action.</p>
      <p>The July 11th 2010 Version of NDF-RT was used
in the evaluation.</p>
      <p>
        SNOMED CT is currently the largest clinical
terminology. It is developed and maintained
by the International Health Terminology Standard
Development Organization (IHTSDO) [
        <xref ref-type="bibr" rid="ref4">4</xref>
        ]. In
SNOMED CT, the drugs are simply related to
pharmacologic classes through the isa relationship.
For example, there is an isa relationship between the
drug Quinine and the class Cinchona antimalarial.
The January 31, 2010 Version of SNOMED CT was
used in the study.
      </p>
      <p>
        Related Work. Others have examined many
aspects of NDF-RT. [
        <xref ref-type="bibr" rid="ref5">5</xref>
        ] investigated the coverage
of the Physiologic Effects hierarchy in
NDFRT. It was found that the physiologic effects
category was sufficient for classifying medications.
[
        <xref ref-type="bibr" rid="ref6">6</xref>
        ] investigated the addition of pharmacogenomics
into the hierarchy. [
        <xref ref-type="bibr" rid="ref7">7</xref>
        ] applied NDF-RT to mapping
text from medication lists at the Mayo Clinic
using the SmartAccess Vocabulary Server.
NDFRT covered 97.8% of the concepts found in the
medication lists, indicating NDF-RT can be used
in a clinical setting for medication purposes. [
        <xref ref-type="bibr" rid="ref8">8</xref>
        ]
compared NDF-RT to the National Drug File,
Medicare Part D and a proprietary knowledge base.
It was determined that 76% of the classes from the
three original terminologies were contained in
NDFRT. In recent work, [
        <xref ref-type="bibr" rid="ref9">9</xref>
        ] evaluated the correspondence
of NDF-RT drugs and classes to RxNorm drugs and
classes. As of October 2009, approximately 50% of
the drugs did not correspond between terminologies.
[
        <xref ref-type="bibr" rid="ref10">10</xref>
        ] mapped medications to diseases, showing a
clear example of how NDF-RT can be applied in
clinical decision support situations. As another
example of clinical applications [
        <xref ref-type="bibr" rid="ref11">11</xref>
        ] integrated
NDFRT into the process of generating structured product
labeling. Finally, [
        <xref ref-type="bibr" rid="ref12">12</xref>
        ] used the NDF-RT drug classes
to determine the anti-coagulation status of patients
based on their medication list, demonstrating a first
step in clinical decision support.
      </p>
      <p>Our study focuses not on content coverage, but
rather on interoperability among systems of drug
classes in various terminologies, including NDF-RT
and SNOMED CT. These terminologies were chosen
as a reference because they contain drug hierarchies,
are mature, and are widely used. More specifically,
we want to assess whether similar sets of drugs are
linked to the same classes in different systems.</p>
      <p>
        As part of the evaluation, we use a concept
alignment technique described by [
        <xref ref-type="bibr" rid="ref13">13</xref>
        ]. NDF-RT was
loaded into a Virtuoso endpoint [
        <xref ref-type="bibr" rid="ref14">14</xref>
        ] for SPARQL
querying, which allowed for evaluation of the drug
classes.
      </p>
    </sec>
    <sec id="sec-3">
      <title>Methods</title>
      <p>To evaluate the drug classes in NDF-RT, we
developed an extensional method of evaluation,
comparing between VA classes and SNOMED CT
drug classes. Instead of comparing pharmacologic
classes based on lexical resemblance of their names,
we compare the extensions of these classes.</p>
      <p>The extension of a pharmacologic class is the set
of drugs a class has as members. The degree to which
any two drug classes are similar was determined by
the overlap of their extensions. This is measured by
the Jaccard Coefficient,</p>
      <p>
        J (A, B) =
|A ∩ B|
|A ∪ B|
,
where the intersection is the number of drugs which
are the same between any two classes and the union
is the total number of drugs between any two drug
classes [
        <xref ref-type="bibr" rid="ref15">15</xref>
        ]. An example of extension is presented in
Figure 1a. Here, the VA class THROMBOLYTICS
and the SNOMED CT class Thrombolytic share
6 drugs, including streptokinase, while the drug
drotrecogin is specific to the SNOMED CT class.
The Jaccard value is computed as the cardinality
of the intersection (6) over that of the union of the
classes (7), i.e., 0.86. (In actuality, the classes are
compared, not based on the ingredients, but based
on the clinical drugs they have as members. The
corresponding ingredients are shown in Figure 1a for
brevity.)
      </p>
      <p>The extension of each VA class is compared to
that of every class in SNOMED CT. For a given VA
class, the SNOMED CT class for which the highest
Jaccard value is found is selected as the best match.
The average Jaccard of the pairwise comparisons
between NDF-RT and SNOMED CT is used to
summarize the external comparison and determine
the overall similarity between the two class systems.</p>
      <p>To obtain an extension, the clinical drug
members of a drug class were obtained. As opposed
to VA (where drug classes are linked directly to
clinical drugs), in SNOMED CT, the ingredients of
a class were first obtained, then the clinical drugs
for those ingredients were obtained using relations
in NDF-RT, thus keeping the domain of clinical
drugs limited to only NDF-RT. In addition, the drug
members of a class included its drugs and all drugs
which were members of any subclasses. For example,
the clinical drug QUININE SO4 260MG TAB is
linked directly to the VA class ANTIMALARIALS,
but is also considered a member of the its
parent class ANTIPROTOZOALS. Using the drug
members, the drug member intersection was found,
comparing the extension of the VA classes to the
SNOMED CT classes.</p>
    </sec>
    <sec id="sec-4">
      <title>Results</title>
      <p>There are 485 VA and 722 SNOMED CT classes.
To reduce comparisons (and noise), classes which
did not have any drug members were removed.
There were 95 VA (20%) and 195 SNOMED CT
(27%) classes without members. Examples of classes
with no members include INVESTIGATIONAL
ANTI-TUBERCULAR DRUGS (VA),
ANTIFUNGALS,TOPICAL OTIC (VA), Antineoplastic
alkaloid (SNOMED CT) and Corticosteroids used in the
treatment of asthma (SNOMED CT).</p>
      <p>Among the 15,027 clinical drugs in NDF-RT,
8414 correspond to ingredients also present in
SNOMED CT. Examples of clinical drugs specific
to NDF-RT include medicinal products from classes
such as HERBS/ALTERNATIVE THERAPIES
(e.g.,WILD CHERRY BARK PWDR).</p>
      <p>The extensional comparison was obtained by
calculating the overlap between the sets of drug
members of class pairs and can be summarized by
the average Jaccard coefficient for all class pairs
between NDF-RT and SNOMED CT. Through their
average Jaccard value, pairs of pharmacologic class
systems can be compared for their overall similarity.
The average Jaccard value is 0.293, indicating
limited overlap overall between drug extensions
across the two class systems.</p>
      <p>The distribution of the average highest Jaccard
value for the VA classes is shown in Figure
1b. Very few classes exhibit complete overlap
(Jaccard = 1.0). Examples include the VA class
DIRECT RENIN INHIBITOR and the SNOMED
CT class Renin Inhibitor. This particular class
contains the clinical drugs corresponding to only
one ingredient, aliskiren. The proportion of VA
classes with a Jaccard value of 0.75 or above is
11.5%. For example, the Jaccard value for the
overlap between the VA class THROMBOLYTICS
and the SNOMED CT class thrombolytic is 0.86. As
shown in Figure 1a, the clinical drugs corresponding
to six ingredients are common to both the VA class
and the SNOMED CT class. These ingredients
are alteplase, anistreplase, reteplase, streptokinase,
tenecteplase and urokinase. Additionally, SNOMED
CT also lists drotrecogin as a member of the class
thrombolytic, although the indications for this drug
seem to be limited to severe sepsis.</p>
      <p>Finally, 75.6% of the VA classes have a
Jaccard value lower than 0.5. For example,
the Jaccard value for the overlap between the
VA class HYPEROSMOTIC LAXATIVES and the
SNOMED CT class osmotic laxatives is only 0.16.
While clinical drugs corresponding to the ingredients
lactulose and magnesium sulfate are common to
both classes, many clinical drugs found in the VA
class are not in the SNOMED CT class (e.g., other
magnesium salts such as magnesium biphosphate
and magnesium hydroxide). Interestingly, clinical
drugs corresponding to magnesium hydroxide are
part of a different SNOMED CT class, saline
hydroxide. Conversely, solutions of glycerol are
classified as osmotic laxatives in SNOMED CT, but
as LAXATIVES, RECTAL in NDF-RT.</p>
    </sec>
    <sec id="sec-5">
      <title>Discussion</title>
      <sec id="sec-5-1">
        <title>Overlap among Class Systems</title>
        <p>The similarity among the two pharmacologic class
systems under investigation (VA and SNOMED
CT) is relatively limited. The average Jaccard
values among classes based on shared drugs is
0.293. The following reasons can be proposed as
an explanation, in addition to sheer differences
in classification and discrepancies illustrated in
the section above. In some cases, there is no
equivalent class in SNOMED CT for a given
VA class, especially for high-level aggregation
classes (e.g., BLOODPRODUCTS / MODIFIERS
/ VOLUME EXPANDERS ), residual classes (e.g.,
CARDIOVASCULAR AGENTS, OTHERS ) and
classes specific to topical forms (e.g.,
BETABLOCKERS, TOPICAL OPHTALMIC ). Another
reason is that partially overlapping classes are
defined using different classificatory criteria. For
example, ophtalmic forms of beta-blockers such
as TIMOLOL MALEATE 0.5% GEL, OPH are
classified as BETA-BLOCKERS, TOPICAL
OPHTALMIC in NDF-RT and as anti glaucoma agent
in SNOMED CT. While the former class only
contains beta-blockers, the latter includes a wider
range of products (e.g., apraclonidine). Another
difference between the two class systems is that
the pharmacologic class is a property of the clinical
drug for the VA classes, whereas it is inherited
through the ingredient for SNOMED CT classes.
For example, injectable forms of acetylcysteine
are classified as ANTIDOTES/DETERRENTS,
OTHERS in NDF-RT, while topical solutions (e.g.,
for inhalation) are classified as MUCOLYTICS. In
contrast, all forms of this drug are classified as
both drugs used in the treatment of paracetamol
poisoning and mucolytic agent in SNOMED CT.
Finally, we also found a limited number of errors,
such as the classification of the antibacterial drug
NORFLOXACIN 0.3% SOLN, OPH as
BETABLOCKERS, TOPICAL OPHTALMIC in
NDFRT.</p>
      </sec>
      <sec id="sec-5-2">
        <title>Classes without Drug Members</title>
        <p>One particular difference between the two
pharmacologic class systems is the number of classes for
which there is no drug in NDF-RT. (These classes
were omitted from our statistics). These differences
have different causes in different systems. For VA
classes, most classes with no drugs correspond to
investigational drugs. In contrast, in SNOMED
CT, such classes correspond essentially to classes for
which the corresponding medicinal products are out
of the scope of NDF-RT, including blood products
(e.g., Red cells - irradiated ), dietary products (e.g.,
Gluten free food product ) and various prescribable
entities (e.g., Sterile maggots).</p>
      </sec>
      <sec id="sec-5-3">
        <title>Consequences for Semantic Mining</title>
        <p>As the sets of drugs available in terminological
systems vary considerably across systems, with
minimal overlap among them, annotation of the
literature directly with classes from a given system
is likely to result in annotated datasets that will
not be interoperable, and whose annotations will be
difficult to reconcile. Even if some terminologies
such as SNOMED CT and NDF-RT tend to
provide good coverage of clinical drugs, their overlap
with other terminologies in terms of pharmacologic
classes remains limited.</p>
        <p>In practice, a better option for semantic mining is
to annotate drugs rather than pharmacologic classes.
Drugs names are relatively standard (at least at
the ingredient level) and integration resources such
as RxNorm are already available. Once resources
have been annotated at the ingredient level, the
corresponding classes can be added automatically
in reference to the most useful pharmacologic
class system in a particular context. Annotations
to another pharmacologic class system can be
recomputed from the ingredients in case of reuse of
these resources for a different purpose.</p>
      </sec>
      <sec id="sec-5-4">
        <title>Limitations and Future Work</title>
        <p>There are a few limitations to this work. The
evaluation was only a quantitative evaluation,
comparing the two terminologies. It was not an
evaluation of the clinical quality or the use of
NDFRT in a clinical situation. In addition, the domain
of drugs used in the comparison was only clinical
drugs in NDF-RT, as we assumed the clinical drugs
to be complete. No comparisons were done at
the ingredient level. Because of this, we obtained
all the NDF-RT clinical drugs of an ingredient
from the terminology. Some classes that have no
drugs members may have had ingredients; however,
these ingredients were either not present in
NDFRT or they did not have clinical drugs associated
with them, resulting in the class not having drug
members.</p>
        <p>
          For a complete evaluation of NDF-RT, the
external pharmacologic classes (EPCs) will be
included in future work. To leverage these classes,
they first must be enriched with drugs. A technique
to do such an operation has been piloted by [
          <xref ref-type="bibr" rid="ref12">12</xref>
          ],
which utilizes a description logics based classifier to
classify drugs into EPCs.
        </p>
        <p>In addition to the extensional approach used in
this study, we would like to explore an intensional
approach to comparing the classes, leveraging
synonymy relations in the Unified Medical Language
System (UMLS). In practice, classes across systems
could be mapped through the UMLS and the
extensions of equivalent classes could be compared.</p>
        <p>Finally, this work may be considered a class
centric approach, focused around drugs associated
with classes. Future work will include a drug centric
approach, which focuses on classes associated with
drugs. More specifically, we will study the set of
pharmacologic classes associated with a given drug
in different pharmacologic class systems.
By using an automated method of comparing
classes using drug class extensions, inconsistencies
between terminologies were discovered. These
inconsistencies serve as an indicator for possible
review. The automated method of pairwise class
member comparison complements standard lexical
matching and can serve as an additional quality
assurance tool for terminologies. This methodology
sets a framework for pairwise comparison of
drug classes between terminological systems using
only their drug members. Finally, due to the
heterogeneity of the representation of pharmacologic
classes in various terminologies, we recommend that
drugs, not classes, be annotated in text for semantic
mining purposes.</p>
      </sec>
    </sec>
    <sec id="sec-6">
      <title>Competing interests</title>
      <p>The authors declare that they have no competing
interests.</p>
    </sec>
    <sec id="sec-7">
      <title>Authors’ contributions</title>
      <p>Jonathan Mortensen and Olivier Bodenreider
conceived and designed the study. Jonathan Mortensen
acquired the data and performed the analysis and
interpretation of the data. Both authors contributed
to the redaction of the manuscript and approved its
final version.</p>
    </sec>
    <sec id="sec-8">
      <title>Acknowledgements</title>
      <p>This research was supported in part by the Intramural
Research Program of the National Institutes of Health
(NIH), National Library of Medicine (NLM) in addition
to the Choose Ohio First Scholarship Program.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <mixed-citation>
          1.
          <string-name>
            <surname>Carter</surname>
            <given-names>JS</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Brown</surname>
            <given-names>SH</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Erlbaum</surname>
            <given-names>MS</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Gregg</surname>
            <given-names>W</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Elkin</surname>
            <given-names>PL</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Speroff</surname>
            <given-names>T</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Tuttle</surname>
            <given-names>MS</given-names>
          </string-name>
          :
          <article-title>Initializing the VA medication reference terminology using UMLS metathesaurus co-occurrences</article-title>
          .
          <source>In Proceedings of the AMIA Symposium</source>
          <year>2002</year>
          :
          <fpage>116</fpage>
          -
          <lpage>20</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref2">
        <mixed-citation>
          2.
          <string-name>
            <surname>Miller</surname>
            <given-names>RA</given-names>
          </string-name>
          :
          <article-title>Clinical Decision Support and Electronic Prescribing Systems: A Time for Responsible Thought and Action</article-title>
          .
          <source>Journal of the American Medical Informatics Association</source>
          <year>2005</year>
          ,
          <volume>12</volume>
          (
          <issue>4</issue>
          ):
          <fpage>403</fpage>
          -
          <lpage>409</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref3">
        <mixed-citation>
          3.
          <string-name>
            <surname>Lincoln</surname>
            <given-names>MJ</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Brown</surname>
            <given-names>SH</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Nguyen</surname>
            <given-names>V</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Cromwell</surname>
            <given-names>T</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Carter</surname>
            <given-names>J</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Erlbaum</surname>
            <given-names>M</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Tuttle</surname>
            <given-names>M</given-names>
          </string-name>
          :
          <article-title>US Department of Veterans Affairs enterprise reference terminology strategic overview</article-title>
          .
          <source>Medinfo</source>
          <year>2004</year>
          ,
          <volume>11</volume>
          (Pt 1):
          <fpage>391</fpage>
          -
          <lpage>395</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref4">
        <mixed-citation>
          4.
          <string-name>
            <surname>SNOMED CT</surname>
          </string-name>
          (
          <article-title>Systematized Nomenclature of Medicine-Clinical Terms</article-title>
          )[http://www.ihtsdo.org/ snomed-ct/].
        </mixed-citation>
      </ref>
      <ref id="ref5">
        <mixed-citation>
          5.
          <string-name>
            <surname>Rosenbloom</surname>
            <given-names>ST</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Awad</surname>
            <given-names>J</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Speroff</surname>
            <given-names>T</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Elkin</surname>
            <given-names>PL</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Rothman</surname>
            <given-names>R</given-names>
          </string-name>
          ,
          <string-name>
            <surname>III</surname>
            <given-names>AS</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Peterson</surname>
            <given-names>J</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Bauer</surname>
            <given-names>BA</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Wahner-Roedler</surname>
            <given-names>DL</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Lee</surname>
            <given-names>M</given-names>
          </string-name>
          , et al.:
          <article-title>Adequacy of representation of the National Drug File Reference Terminology Physiologic Effects reference hierarchy for commonly prescribed medications</article-title>
          .
          <source>In AMIA Annu Symp Proc</source>
          <year>2003</year>
          :
          <fpage>569</fpage>
          -
          <lpage>78</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref6">
        <mixed-citation>
          6.
          <string-name>
            <surname>Chute</surname>
            <given-names>CG</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Carter</surname>
            <given-names>JS</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Tuttle</surname>
            <given-names>MS</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Haber</surname>
            <given-names>M</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Brown</surname>
            <given-names>SH</given-names>
          </string-name>
          :
          <article-title>Integrating pharmacokinetics knowledge into a drug ontology as an extension to support pharmacogenomics</article-title>
          .
          <source>In AMIA Annu Symp Proc</source>
          <year>2003</year>
          :
          <fpage>170</fpage>
          -
          <lpage>4</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref7">
        <mixed-citation>
          7.
          <string-name>
            <surname>Brown</surname>
            <given-names>SH</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Elkin</surname>
            <given-names>PL</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Rosenbloom</surname>
            <given-names>ST</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Husser</surname>
            <given-names>C</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Bauer</surname>
            <given-names>BA</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Lincoln</surname>
            <given-names>MJ</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Carter</surname>
            <given-names>J</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Erlbaum</surname>
            <given-names>M</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Tuttle</surname>
            <given-names>MS</given-names>
          </string-name>
          :
          <article-title>VA National Drug File Reference Terminology: a cross-institutional content coverage study</article-title>
          .
          <source>Medinfo</source>
          <year>2004</year>
          ,
          <volume>11</volume>
          (Pt 1):
          <fpage>477</fpage>
          -
          <lpage>81</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref8">
        <mixed-citation>
          8.
          <string-name>
            <surname>Carter</surname>
            <given-names>JS</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Brown</surname>
            <given-names>SH</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Bauer</surname>
            <given-names>BA</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Elkin</surname>
            <given-names>PL</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Erlbaum</surname>
            <given-names>MS</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Froehling</surname>
            <given-names>DA</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Lincoln</surname>
            <given-names>MJ</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Rosenbloom</surname>
            <given-names>ST</given-names>
          </string-name>
          ,
          <string-name>
            <surname>WahnerRoedler</surname>
            <given-names>DL</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Tuttle</surname>
            <given-names>MS</given-names>
          </string-name>
          :
          <article-title>Categorical information in pharmaceutical terminologies</article-title>
          .
          <source>In AMIA Annu Symp Proc</source>
          <year>2006</year>
          :
          <fpage>116</fpage>
          -
          <lpage>20</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref9">
        <mixed-citation>
          9.
          <string-name>
            <surname>Pathak</surname>
            <given-names>J</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Chute</surname>
            <given-names>CG</given-names>
          </string-name>
          :
          <article-title>Analyzing categorical information in two publicly available drug terminologies: RxNorm and NDF-RT</article-title>
          .
          <source>Journal of the American Medical Informatics Association</source>
          <year>2010</year>
          ,
          <volume>17</volume>
          (
          <issue>4</issue>
          ):
          <fpage>432</fpage>
          -
          <lpage>439</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref10">
        <mixed-citation>
          10.
          <string-name>
            <surname>Burton</surname>
            <given-names>MM</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Simonaitis</surname>
            <given-names>L</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Schadow</surname>
            <given-names>G</given-names>
          </string-name>
          :
          <article-title>Medication and Indication Linkage: A Practical Therapy for the Problem List?</article-title>
          <source>In AMIA Annual Symposium Proceedings</source>
          <year>2008</year>
          :
          <fpage>86</fpage>
          -
          <lpage>90</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref11">
        <mixed-citation>
          11.
          <string-name>
            <surname>Schadow</surname>
            <given-names>G</given-names>
          </string-name>
          :
          <article-title>Structured product labeling improves detection of drug-intolerance issues</article-title>
          .
          <source>Journal of the American Medical Informatics Association</source>
          <year>2009</year>
          ,
          <volume>16</volume>
          (
          <issue>2</issue>
          ):
          <fpage>211</fpage>
          -
          <lpage>219</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref12">
        <mixed-citation>
          12.
          <string-name>
            <surname>Bodenreider</surname>
            <given-names>O</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Mougin</surname>
            <given-names>F</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Burgun</surname>
            <given-names>A</given-names>
          </string-name>
          :
          <article-title>Automatic determination of anticoagulation status with NDF-RT</article-title>
          .
          <source>In Proceedings of the 13th ISMB'2010 SIG meeting ”</source>
          Bio-ontologies”
          <year>2010</year>
          :
          <fpage>140</fpage>
          -
          <lpage>143</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref13">
        <mixed-citation>
          13.
          <string-name>
            <surname>Bodenreider</surname>
            <given-names>O</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Burgun</surname>
            <given-names>A</given-names>
          </string-name>
          :
          <article-title>Aligning knowledge sources in the UMLS: methods, quantitative results, and applications</article-title>
          .
          <source>In Stud Health Technol Inform</source>
          , Volume
          <volume>107</volume>
          (
          <issue>Pt 1</issue>
          )
          <year>2004</year>
          :
          <fpage>327</fpage>
          -
          <lpage>31</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref14">
        <mixed-citation>
          14.
          <string-name>
            <surname>Virtuoso</surname>
          </string-name>
          <article-title>Universal openlinksw</article-title>
          .com/].
        </mixed-citation>
      </ref>
      <ref id="ref15">
        <mixed-citation>
          15.
          <string-name>
            <surname>Jaccard</surname>
            <given-names>P</given-names>
          </string-name>
          :
          <article-title>E´tude comparative de la distribution florale dans une portion des Alpes et des Jura</article-title>
          . Bulletin
          <string-name>
            <surname>de la Soci</surname>
          </string-name>
          ´et´e
          <source>Vaudoise des Sciences Naturelles</source>
          <year>1901</year>
          , (
          <volume>37</volume>
          ):
          <fpage>547</fpage>
          -
          <lpage>579</lpage>
          .
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>